Transgene is designing and developing next-generation immunotherapeutics against cancer
TG4001
Positive Interim Analysis Results
of Phase II Trial
Evaluating TG4001 + Avelumab
vs Avelumab in HPV-Positive Anogenital Cancers
TG4050
First positive data
from Phase I clinical trials
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our two therapeutic approaches
Discover our technologies
One patient, one cancer, one vaccine
With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.
myvac® video Discover myvac®
A new generation of products
These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.
Discover invir.IO™
TG4001
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.
More information
Transgene presents data confirming the potential of oncolytic virus TG6002 administered intravenously 
Transgene in a nutshell
ESMO 2021
Donwload Press release (PDF)
TG6002 en images
Press releases
- November 14, 2022 - Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
- November 7, 2022 - Transgene reports business update and Q3 2022 financial position
- November 2, 2022 - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
- September 27, 2022 - R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
Last publications
- September 11, 2022 - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
- April 12, 2022 - Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- January 19, 2022 - Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
- September 23, 2021 - Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
Latest webcasts
- September 7, 2022 - 2022 Half-year results and business update
- December 15, 2021 - License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO™ Platform
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
